A phase II study of @entity1260 /mesna with XXXX for @entity242 .

@entity1 @entity632 @entity242 @entity75 @entity1260 @entity2131
In a phase II study, 16 adult @entity1 with locally advanced or metastatic soft tissue @entity242 were treated with i.v. infusions of @entity1260 /mesna 5 g/m2 plus i.v. @entity632 40 mg/m2. Courses were given every 3 weeks up to a maximum of six courses in responding @entity1 . Six @entity1 (37.5%) had either complete (1 @entity1 ) or partial responses (5 @entity1 ). Confidence limits for this response rate were 15.2%-64.5% (95% confidence level). There was one toxic death in association with @entity75 , renal and @entity2131 . Unilateral pneumothoraces occurred in 2 @entity1 with large pulmonary metastases. Recurrent severe @entity1260 /mesna @entity75 occurred in 2 @entity1 at risk for this complication; @entity1 who develop severe @entity1260 /mesna @entity75 should not be retreated with this drug. @entity1260 /mesna with @entity632 is an active combination to treat @entity242 but, despite the feasibility of the combination, sequential monotherapy with these drugs might provide similar or better clinical benefit.
